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Induction of GADD45 and JNK/SAPK-Dependent
Apoptosis following Inducible Expression of BRCA1
(Wu et al., 1996). Initial insight into the functional prop-
erties of BRCA1 has been inferred from its pattern of
subnuclear localization (Scully et al., 1997b). During S
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Fred C. Christians,2 Leif W. Ellisen,1 phase, the endogenous protein is present within nuclear
dots that are partially colocalized with RAD51, the mam-Shyamala Maheswaran,1,7 Jonathan D. Oliner,2
and Daniel A. Haber1,3 malian homolog of bacterial recA, involved in homolo-
gous recombination and the repair of double-strand1 Massachusetts General Hospital Cancer Center and
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1997; Scully et al., 1997c; Thomas et al., 1997). BRCA1
is also localized in centrosomes during M phase, and
mouse embryo fibroblasts with a partial loss-of-functionSummary
phenotype demonstrate chromosomal abnormalities,
associated with centrosome amplification (Hsu andThe breast cancer susceptibility gene BRCA1 encodes
White, 1998; Xu et al., 1999).a protein implicated in the cellular response to DNA
A distinct role for BRCA1 has been proposed in tran-damage, with postulated roles in homologous recom-
scriptional regulation. Protein purification studies havebination as well as transcriptional regulation. To iden-
shown that BRCA1 coelutes with the RNA polymerasetify downstream target genes, we established cell lines
II holoenzyme complex (Scully et al., 1997a), and it maywith tightly regulated inducible expression of BRCA1.
interact with RNA helicase (Anderson et al., 1998) andHigh-density oligonucleotide arrays were used to ana-
the transcriptional regulators p53 (Ouichi et al., 1998;lyze gene expression profiles at various times fol-
Zhang et al., 1998), CtIp (Yu et al., 1998), and c-Myclowing BRCA1 induction. A major BRCA1 target is
(Wang et al., 1998). The C-terminal domain of BRCA1the DNA damage±responsive gene GADD45. Induction
mediates transcriptional activation when fused to a het-of BRCA1 triggers apoptosis through activation of
erologous DNA-binding domain (Chapman and Verma,c-Jun N-terminal kinase/stress-activated protein ki-
1996; Monteiro et al., 1996). Transient tranfection ofnase (JNK/SAPK), a signaling pathway potentially linked
BRCA1 expression constructs leads to transcriptionalto GADD45 gene family members. The p53-indepen-
activation of the promoter of the cyclin-dependent ki-dent induction of GADD45 by BRCA1 and its activation
nase inhibitor p21, through both p53-dependent andof JNK/SAPK suggest a pathway for BRCA1-induced
p53-independent pathways (Somasundaram et al., 1997;apoptosis.
Ouichi et al., 1998; Zhang et al., 1998). BRCA1 has there-
fore been implicated in genomic stability, through mech-
anisms that may involve transcriptional regulation asIntroduction
well as the maintenance of chromosomal integrity.
Definitive studies of BRCA1 function have been ham-BRCA1 encodes a tumor suppressor gene that is mu-
tated in the germline of women with a genetic predispo- pered by the absence of BRCA1-null cell lines and the
difficulty in achieving stable expression of a transfectedsition to breast and ovarian cancer (Miki et al., 1994).
Inactivation of BRCA1 in the mouse is an early embry- full-length cDNA (Holt et al., 1996; Shao et al., 1996).
To address the functional properties of BRCA1 and toonic lethal (Hakem et al., 1996; Liu et al., 1996), and the
transcript is present at low levels in all cells, although examine its effect on endogenous target genes, we de-
veloped cells in which a tightly regulated inducible pro-high levels of expression are observed in the proliferat-
ing and differentiating cells of tissues such as mammary moter allowed expression of the full-length protein. Oli-
gland and skin (Lane et al., 1995; Marquis et al., 1995). gonucleotide array±based expression profiling revealed
BRCA1 encodes a nuclear polypeptide of 220 kDa with- a small number of genes exhibiting altered expression
out homology to other known proteins. An N-terminal following BRCA1 induction. Among these candidate
ring finger domain mediates a physical interaction with BRCA1 targets, the most dramatic and immediate induc-
BARD1, another ring finger protein of unknown function tion was that of the DNA damage±responsive gene
GADD45. Consistent with the recent report that GADD45
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Figure 1. Inducible Expression of BRCA1
(A) Northern blot analysis of total cellular RNA from cells with inducible expression of BRCA1 (24 hr after tetracycline withdrawal): U2OS-
derived UBR60 (wild-type BRCA1) and UBR60-mt cells (mutant BRCA1), and MDA435-derived MBR62 cells (wild-type BRCA1). The endogenous
BRCA1 transcript is denoted by an asterisk; inducible full-length BRCA1 mRNA is labeled by arrowheads, along with smaller mRNA species,
produced by activation of cryptic splice sites. Loading control, GAPDH.
(B) Immunoblotting analysis of BRCA1 immunoprecipitates, showing tightly regulated inducible expression of the full-length protein in UBR60
and MBR62 cells and of the truncated mutant in UBR60-mt cells. The 12-CA-5 antibody, directed against the synthetic HA N-terminal epitope,
was used to probe cellular lysates immunoprecipitated using either the C-terminal antibody C20 (for full-length BRCA1) or the N-terminal
antibody D20 (for the truncated product).
(C) Immunofluorescence analysis of UBR60 cells grown in the presence or absence of tetracycline. Antibody MS13 recognizes both endogenous
and inducible BRCA1. Hoechst staining shows a primarily nuclear staining of BRCA1.
(D) Northern blot analysis showing restoration of BRCA1 expression by 5-azacytidine treatment of cells that had lost inducible expression
following prolonged growth in the presence of tetracycline, due to presumptive methylation of the inducible promoter.
Results stop codon in the central exon 11, a common site of
breast cancer±associated truncating mutations (UBR60-
mt cells). These cells also demonstrated tightly regu-Inducible Expression of BRCA1
To study the functional properties of BRCA1, we estab- lated expression of the mutant transcript and of the
expected truncated protein of z50 kDa, identified bylished inducible, tetracyline-regulated expression (Gossen
and Bujard, 1992) in two cell types: UBR60 cells, derived immunoprecipitation with the N-terminal antibody D-20,
followed by Western analysis with 12-CA-5 (Figures 1Afrom the U2OS osteosarcoma cell line and MBR62 cells,
derived from the MDA435 breast cancer cell line. North- and 1B).
We used immunofluorescence analysis, with antibodyern and Western blot analyses in both cell lines showed
tightly regulated induction of BRCA1 expression (Fig- MS13 directed against the N terminus of BRCA1, to
compare expression of inducible BRCA1 with that of theures 1A and 1B). Low levels of endogenous 7.8 kb
BRCA1 mRNA were detectable when cells were grown endogenous protein within individual cells (Figure 1C).
Nuclear expression of inducible BRCA1 was evident,in the presence of tetracycline, and drug withdrawal led
to induction of the expected 5.6 kb transfected BRCA1 although some cytoplasmic staining was also observed
in rare cells expressing high levels of BRCA1. Similartranscript. A number of smaller mRNA species were also
observed, presumably resulting from the activation of results were obtained with antibody 12-CA-5 (data not
shown). Cellular heterogeneity, a common feature ofcryptic splice sites within the transfected cDNA (Wilson
et al., 1997), but these comprised only a small fraction tetracyline-inducible cell lines, was evident following
withdrawal of tetracycline, with the range of inducibleof the polyadenylated transcript (data not shown). Analy-
sis of inducible protein expression, using immunopre- expression estimated as 2- to 10-fold that of the endoge-
nous protein (see below). This relatively modest proteincipitation with antibody C20 directed against the C ter-
minus of BRCA1, followed by immunoblotting using induction, compared with the more dramatic induction
of BRCA1 mRNA (Figure 1A), is consistent with reducedantibody 12-CA-5 against the N-terminal epitope tag,
identified only the expected 220 kDa full-length BRCA1 translational efficiency of the transfected transcript. It
was noted that UBR60 cells lost inducible BRCA1(Figure 1B). U2OS cells were also generated with induc-
ible expression of a mutant BRCA1 allele, containing a expression following continued growth in tetracycline,
Induction of GADD45 and JNK/SAPK by BRCA1
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Figure 2. BRCA1 Induction of p53-Indepen-
dent Apoptosis and Inhibition by bcl2
(A) Colony formation by UBR60 cells (wild-
type p53), UBR60-E6 (expressing HPV16 E6),
and MBR62 (mutant p53), following growth in
the presence or absence of tetracycline. As a
control, UBR-mt cells are shown, expressing
inducible BRCA1 encoding a stop codon in
exon 11. Plates were stained after 14 days in
culture, and colony numbers are expressed
as percent of controls.
(B) Loss of BRCA1-expressing cells following
withdrawal of tetracycline. Northern blot
demonstrating the time course of BRCA1 ex-
pression following tetracycline withdrawal in
UBR60, MBR62, UBR60-bcl2 (expressing
bcl2), and UBR-mt cells. A 4 hr exposure is
shown for UBR60-bcl2 cells, compared with
a 24 hr exposure for UBR60, MBR62, and
UBR60-mt cells. The endogenous BRCA1
transcript (asterisk) is shown, along with the
full-length inducible transcript and a short-
ened nonpolyadenylated inducible species
(arrowheads), and GAPDH (loading control).
(C) (Upper panel) Expression of inducible HA-
BRCA1 in UBR60 and UBR60-bcl2 cells.
Equal amounts of cellular lysates from these
two cell lines, grown in the presence or ab-
sence (24 hr) of tetracycline, were immuno-
precipitated with antibody C20 and analyzed
by Western blot using antibody 12-CA-5, di-
rected against the HA epitope. (Lower panel)
Total cellular levels of BRCA1 protein in
UBR60-bcl2 cells following withdrawal of tet-
racycline, compared with endogenous pro-
tein in these cells (1 tet) and in the breast
cancer cell line MCF7. Equal amounts of cel-
lular lysates were immunoprecipitated with
antibody C20, followed by Western blotting
using monoclonal antibody MS110 against
BRCA1. The breast cancer cell line HCC1937,
which has a homozygous truncating mutation upstream of the C-terminal epitope recognized by antibody C20, is used as a negative control.
(D) Immunoblot of UBR60-bcl2 cells to demonstrate expression of the stably transfected CMV-driven bcl2. Northern blot of UBR60-E6 cells
showing expression of the stably transfected HPV16 E6. p21 immunoblot of UBR60-E6 cells to demonstrate the reduction in baseline p21
expression, following disruption of the endogenous p53 pathway, as well as the failure of IR (20Gy) to induce p21 expression in these cells.
(E) Initiation of apoptosis in UBR60-bcl2 cells, 48 hr following tetracycline withdrawal, demonstrated by PARP cleavage.
(F) TUNEL assay to demonstrate representative apoptotic cells, along with nuclear condensation by Hoechst staining, 48 hr following tetracycline
withdrawal in UBR60-bcl2 cells.
despite retaining the ability to express a transiently p53 is wild-type (Kastan et al., 1992). To confirm that
p53, a tumor suppressor known to trigger apoptosis intransfected tetracycline-responsive reporter (data not
shown). Treatment with 5-azacytidine promptly restored response to inappropriate or conflicting growth signals,
was not required for the inhibition of colony formation byinducible BRCA1 expression in these cells (Figure 1D),
suggesting that hypermethylation of the tetracycline- BRCA1, we stably transfected UBR60 cells with human
papillomavirus (HPV16) E6, which targets p53 for degra-responsive BRCA1 promoter was responsible for its
suppression and presumably for the heterogeneity of dation (the resulting cells were called UBR60-E6). West-
ern blotting confirmed the expression of E6 and theBRCA1 expression in these cells.
reduction in both baseline and IR-induced levels of p21
that indicate abrogation of p53 function (Figure 2D).Induction of Apoptosis by BRCA1
To determine the effect of BRCA1 induction in UBR60 Induction of BRCA1 in UBR60-E6 cells inhibited colony
formation to the same extent as in parental UBR60 cells,cells, we first measured their ability to form colonies in
the presence or absence of tetracycline. An 80% reduc- indicating that this effect was independent of p53 (Fig-
ure 2A).tion in colony formation was observed following induc-
tion of BRCA1 (Figure 2A). In contrast, withdrawal of In examining cells at early time points following with-
drawal of tetracycline, we observed that expression oftetracycline had only a very modest effect on colony
formation in UBR60-mt cells, expressing the mutant the induced BRCA1 transcript was unexpectedly tran-
sient. The induced BRCA1 mRNA was first detectableBRCA1 transcript. The inhibition of colony formation by
BRCA1 was also evident in the MBR62 breast cancer in both UBR60 and MBR62 cells at 6 hr, peaked at
24 hr, and declined to virtually undetectable levels bycells. Of note, these cells have mutant endogenous p53
(G to E at codon 226), in contrast to U2OS cells, in which 96 hr (Figure 2B). In contrast, UBR60-mt cells showed
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Figure 3. Fluorescence Images of Oligonu-
cleotide Arrays Hybridized with RNA from
Cells with Inducible BRCA1 Expression
(A) Pseudocolored fluorescence images from
two arrays of the same type hybridized with
RNA from UBR60-bcl2 cells grown in the
presence (left panel) or absence (right panel)
of tetracycline (24 hr). Color scheme ranges
from blue (weakly hybridizing) to yellow and
on to red (strongly hybridizing). The arrayed
oligonucleotides complementary to BRCA1
itself are highlighted by yellow arrows.
(B) High-magnification fluorescence images
of oligonucleotides complementary to BRCA1,
GADD45, and EGR1 over a time course of
BRCA1 induction (0 to 24 hr following tetracy-
cline withdrawal). ªFCº indicates fold change
in expression versus baseline (time point 0).
Each panel displays five ªperfect matchº oli-
gonucleotides (top row of each panel), which
are complementary to the gene being interro-
gated, and five ªmismatchº oligonucleotides
(bottom row of each panel), which are identi-
cal to the perfect match oligonucleotides im-
mediately above them, except for a single
base difference at the central nucleotide po-
sition. The mismatch oligonucleotides serve
as an internal control for hybridization speci-
ficity.
persistent expression of the mutant BRCA1 transcript. 2C). As noted above, the large increase in mRNA expres-
sion was accompanied by only a modest increase inThese observations raised the possibility that cells ex-
pressing wild-type BRCA1 underwent rapid cell death, BRCA1 protein, consistent with poor translational effi-
ciency of the inducible transcript. The total level ofleading to overgrowth by cells that had lost inducible
expression through promoter hypermethylation. As ex- BRCA1 protein expressed in UBR60-bcl2 cells was
3-fold above baseline expression in U2OS cells andpected, this effect was independent of p53, occurring
both in MBR62 cells with mutant endogenous p53 (Fig- 2-fold above that in the breast cancer cell line MCF7
(Figure 2C), a difference consistent with physiologicalure 2B) and in UBR60-E6 cells, with constitutive ex-
pression of HPV16 E6 (data not shown). To determine variation in BRCA1 levels (Lane et al., 1995; Marquis et
al., 1995). We therefore made use of these cells to searchwhether the rapid loss of detectable BRCA1 expression
resulted from apoptosis of BRCA1-expressing cells, we for downstream targets of BRCA1.
stably transfected these cells with a CMV-driven con-
struct encoding the antiapoptotic gene bcl2 (the re- Gene Expression Profiling to Identify
sulting cells were called UBR60-bcl2; Figure 2D). Consti- BRCA1 Targets
tutive expression of bcl2 prevented the loss of inducible A potential role for BRCA1 in transcriptional regulation
BRCA1 expression for up to 96 hr (Figure 2B). To confirm has been suggested by its ability to enhance transac-
tivation of transiently transfected reporter constructsthat inhibition of apoptosis allowed sustained expres-
sion of BRCA1 in UBR60 cells, we also incubated these (Chapman and Verma, 1996; Monteiro et al., 1996; So-
masundaram et al., 1997; Ouichi et al., 1998; Zhang etcells with caspase inhibitors, which effectively block the
initiation of programmed cell death. Consistent with the al., 1998) and by its ability to interact with both RNA
helicase (Scully et al., 1997a; Anderson et al., 1998) andeffect of bcl2, exposure of cells to synthetic, cell-perme-
able, noncleavable analogs of caspase CPP32 known the transcriptional repression cofactor CtIP (Yu et al.,
1998). However, target genes whose expression is defin-to inhibit apoptosis also prevented the loss of BRCA1
expression (data not shown). Continued expression of itively regulated by BRCA1 remain unknown. Therefore,
we searched for endogenous genes whose expressionBRCA1 in UBR60-bcl2 cells eventually overwhelmed the
protective effect of bcl2, resulting in cell death, first levels might be altered following inducible expression
of BRCA1. Messenger RNA was isolated from UBR60-evident by PARP cleavage and TUNEL staining, 48 hr
following withdrawal of tetracycline (Figures 2E and 2F). bcl2 cells at 0, 6, 12, and 24 hr following BRCA1 induc-
tion, biotinylated, and hybridized to high-density oligo-The ability to achieve sustained expression of induc-
ible BRCA1 in cultured cells made it possible to ana- nucleotide arrays representing 6800 known transcripts
and expressed sequence tags (Lockhart et al., 1996;lyze downstream pathways. UBR60-bcl2 cells displayed
tight regulation of inducible BRCA1 expression, as dem- Wodicka et al., 1997). A gene was considered a candi-
date BRCA1 target if it was progressively induced oronstrated using antibody to the HA epitope tag (Figure
Induction of GADD45 and JNK/SAPK by BRCA1
579
Figure 4. Identification of Candidate BRCA1
Targets by Hybridization to Oligonucleotide
Arrays
(A) Summary of results from hybridization to
oligonucleotide arrays representing 6800 ex-
pressed sequences. Labeled RNA probes de-
rived from UBR60-bcl2 cells grown in the
presence of tetracycline, or 6, 12, and 24 hr
following withdrawal of tetracycline, were hy-
bridized to the arrays. Fold induction by
Northern analysis (at 24 hr) is determined
by PhosphorImager quantitation. All genes
showing at least 2-fold induction by Northern
blotting are listed.
(B) Representative Northern blots of candi-
date BRCA1 targets. Total cellular RNA from
UBR60-bcl2 cells grown in the presence or
absence (24 hr) of tetracycline was analyzed
using probes isolated from the candidate
BRCA1 targets.
repressed in at least two different time points following has been inversely correlated with that of BRCA1 (Hon-
koop et al., 1998; Jarvis et al., 1998); although not detect-BRCA1 induction and it exhibited an expression change
of at least 2-fold. To distinguish reproducible expression able by Northern blotting in U2OS cells, regulation of
these genes by BRCA1 may be more evident in otherchanges from those due to random biological variation,
probes complementary to the candidate BRCA1 targets cell types. In summary, of 6800 genes and ESTs interro-
gated by array hybridization, we identified GADD45 andwere used to screen Northern blots containing total RNA
derived from UBR60-bcl2 cells 24 hr following BRCA1 EGR1 as the two targets whose expression in U2OS
cells was most dramatically altered following BRCA1induction.
Potential BRCA1 targets identified by array hybridiza- induction (Figures 3 and 4). We analyzed these further
to examine their potential relationship with the functionaltion experiments are listed, and representative signals
are shown in Figures 3 and 4. BRCA1 mRNA itself was consequences of BRCA1 induction in these cells.
induced 72-fold at 24 hr, a quantitative estimate consis-
tent with that observed by PhosphoImager analysis of
Northern blots. Twenty-three genes and ESTs identified Induction of GADD45 by BRCA1
GADD45 encodes a stress- and DNA damage±respon-as having increased expression following BRCA1 induc-
tion by array hybridization were confirmed as demon- sive gene, initially isolated by virtue of its induction fol-
lowing UV irradiation (Fornace et al., 1988) and recentlystrating at least 2-fold induction by Northern blotting
(Figure 4). Only two genes were induced by at least 10- found to mediate activation of JNK/SAPK by its up-
stream kinase MTK1/MEK4 MAPKKK (Takekawa andfold: the DNA damage±inducible gene GADD45 (35-fold)
and the immediate early gene Early Growth Response Saito, 1998). Induction of GADD45 mRNA was virtually
coincident with BRCA1 expression, detectable within 31 (EGR1) (10-fold). Oligonucleotide array hybridization
also identified a small number of potential targets that hr of tetracycline withdrawal (Figure 5A). The level of
GADD45 induction by BRCA1 in U2OS cells was compa-were repressed following BRCA1 expression, but these
could not be confirmed by Northern blotting, since their rable to that induced by known stimuli, overexpression
of wild-type p53, or IR (20Gy), and higher than that in-baseline expression levels were below detection. How-
ever, two expression changes of possible interest were duced by UV (20J/m2) in these cells (Figure 5B). In UBR60
cells, lacking bcl2, induction of GADD45 was also evi-in the genes Ki-67 (12-fold repression) and prothymosin
a (4-fold repression; data not shown). These genes have dent, mirroring the transient expression of BRCA1 in
these cells (data not shown). At least two distinct path-been previously implicated as possible prognostic mark-
ers in breast cancer, and Ki-67 expression in this tumor ways leading to the induction of GADD45 have been
Cell
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Figure 5. Induction of GADD45 by BRCA1
(A) Northern blot analysis of the time course of induction for GADD45 and EGR1 in UBR60-bcl2 cells, following withdrawal of tetracycline.
Panels represent separate hybridizations to the identical blot. Induction of BRCA1 (within 3 hr) and GAPDH loading control are shown for the
same blot in Figure 2B.
(B) Northern blot analysis, comparing the induction of GADD45 mRNA by BRCA1 in UBR60-bcl2 cells with its induction following overexpression
of wild-type p53. U2OS cells with constitutive expression of a CMV promoter-driven temperature-sensitive p53 allele (tsp53) were incubated
for 18 hr at the permissive temperature, 328C. Induction of GADD45 in U2OS cells is shown following treatment with UV (20 J/m2) and IR
(20Gy).
(C) Activation of GADD45 regulatory sequences by BRCA1. Fold increase in luciferase activity following transient transfection of CMV-BRCA1
(duplicate experiments; 1, hatched and 2, black), relative to CMV vector-transfected cells (white), into U2OS cells or U2OS-E6 cells (expressing
HPV16 E6). Reporter constructs are the empty vector (pGL3), GADD45 intron 1 (1339 to 1824 bp; pI-1), intron 3 (11553 to 11695 bp; pI-3),
and the proximal promoter (11 to 2994 bp upstream of transcriptional start; pP-1). Baseline luciferase activity following transfection of CMV
vector was comparable in all cases (10,000 to 40,000 U).
(D) p53-independent induction of GADD45 mRNA by BRCA1. Northern blot analysis of UBR60-bcl2-E6 cells grown in the presence or absence
(24 hr) of tetracycline, probed for BRCA1, GADD45, and GAPDH (loading control). Expression of the stably tranfected HPV16 E6 is demonstrated
in the inset.
(E) Northern blot demonstrating strong induction of GADD45 mRNA in the breast cancer cell lines MCF7 (wild-type endogenous p53) and
MDA435 (mutant p53), but not HCC1937 (mutant BRCA1 and mutant p53), following treatment with 100 mg/ml MMS.
(F) Western blot showing unaltered expression of the p53 targets p21 and bax following induction of BRCA1 in UBR60-bcl2 cells. Baseline
p53 itself was not detectable by immunoblotting, either in the presence or absence of BRCA1, and p53 levels are therefore shown following
stabilization by UV irradiation, either in the presence or absence of tetracycline.
identified. IR triggers the ATM- and p53-dependent in- a second BRCA1-responsive site within intron 1, which
was also p53 dependent, while the GADD45 proximalduction of GADD45, mediated through a p53-responsive
element within intron 3 (Kastan et al., 1992). Other stim- promoter was not activated by expression of BRCA1
(Figure 5C). To determine whether presence of p53uli, including UV irradiation and treatment with alkylating
agents (so-called ªMUMº stress, for methyl methanesul- was indeed required for BRCA1-mediated induction of
endogenous GADD45, UBR60-bcl2 cells were stablyfonate [MMS], UV irradiation, and medium starvation)
lead to the induction of GADD45 by a p53-independent transfected with HPV16 E6 (resulting cells were called
UBR60-bcl2-E6). However, inactivation of endogenouspathway, which may involve elements within the proxi-
mal GADD45 promoter (Hollander et al., 1993). p53 in these cells did not alter the potent BRCA1-medi-
ated induction of endogenous GADD45 (Figure 5D). Sim-Given previous reports that BRCA1 modulates p53-
mediated transcriptional activation (Ouichi et al., 1998; ilarly, MBR62 cells, harboring mutant endogenous p53,
demonstrated comparable induction of GADD45 follow-Zhang et al., 1998), we first examined the effect of
BRCA1 expression on a promoter reporter containing ing induction of BRCA1 expression (data not shown).
Thus, while transient transfection studies suggest athe p53-responsive site within intron 3 of GADD45.
BRCA1 reproducibly induced 2- to 4-fold transcriptional modest cooperative effect between BRCA1 and p53,
induction of endogenous GADD45 is largely indepen-activation of this reporter following cotransfection into
U2OS cells, but not into U2OS cells expressing HPV16 dent of p53. Since the proximal GADD45 promoter is
not activated following induction of BRCA1 (Figure 5C),E6 (Figure 5C) or into Saos-2 cells, which have a deletion
of endogenous p53 (data not shown). Analysis of other the effect of BRCA1 may be mediated through other
regulatory sequences.potential GADD45 regulatory sequences demonstrated
Induction of GADD45 and JNK/SAPK by BRCA1
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To test the p53-independent pathway leading to the
induction of GADD45, we used MMS, an alkylating agent
known to induce GADD45 in all cells tested (Kastan et
al., 1992). As expected, treatment of both the p53 wild-
type cells MCF7 and the p53 mutant cells MDA435 with
100 mg/ml of MMS resulted in potent induction of
GADD45 (Figure 5E). Remarkably, minimal induction of
GADD45 was observed in HCC1937, a recently discov-
ered breast cancer cell line, harboring a mutation in
both BRCA1 and p53 (Tomlinson et al., 1998). Baseline
expression of GADD45 was elevated in HCC1937 cells
but considerably lower than induced levels in other cell
lines, indicating that induction by MMS would have been
readily detectable. Thus, in this BRCA1 mutant cell line,
the p53-independent regulation of GADD45 appears to
be compromised.
Analysis of Other Potential BRCA1 Targets
Transient transfection of BRCA1 has been shown to result
in activation of the p21 promoter, potentially through both
p53-dependent and p53-independent pathways (Soma-
sundaram et al., 1997; Ouichi et al., 1998; Zhang et al.,
1998). However, we did not detect an alteration in the
expression of either endogenous p53 or p21 transcripts
by Northern blot analysis in cells with inducible BRCA1
expression, nor were p53 or p21 protein levels altered
Figure 6. Activation of JNK/SAPK by BRCA1
by immunoblotting (Figure 5F and data not shown). Ex-
(A) In vitro kinase activity. Endogenous JNK/SAPK was immunopre-pression of p21 was also unaltered following BRCA1
cipitated from UBR60-bcl2 cells grown in the presence or absence
induction in U2OS-E6 cells, in which the lower baseline (24 hr) of tetracycline and used to phosphorylate bacterially pro-
expression of p21 should facilitate detection of a moder- duced c-Jun. Western blotting is shown to demonstrate comparable
amounts of the immunoprecipitated kinase (JNK). For comparison,ate induction (data not shown). Other p53 target genes,
JNK/SAPK activity is shown following treatment of cells with UVincluding bax (Figure 5F) and MDM2 (data not shown),
irradiation. As control, the absence of JNK/SAPK activation associ-were unaffected by inducible expression of BRCA1 in
ated with p53-mediated apoptosis is demonstrated in U2OS cellsUBR60-bcl2 cells. Thus, in the cells analyzed here, we
stably expressing a temperature-sensitive p53 (tsp53).
did not detect induction by BRCA1 of p53 target genes (B) Phosphorylation of endogenous JNK/SAPK following induction
other than GADD45. of BRCA1. Immunoblotting analysis, using anti-phospho JNK anti-
body, of immunoprecipitated JNK/SAPK from UBR60-bcl2 cellsWhile GADD45 was the most highly induced BRCA1
grown in the presence of tetracycline, 24 hr and 36 hr followingtarget identified by hybridization to oligonucleotide arrays,
withdrawal of tetracycline, or 4 hr after treatment with UV (20 J/m2).a second transcript whose expression was significantly
Western blotting using anti-JNK antibody is shown to demonstrateincreased was EGR1. EGR1 encodes a serum-inducible
comparable amounts of the immunoprecipitated kinase (JNK).
zinc finger transcription factor induced following mito- (C) Absence of BRCA1-mediated activation of the MAP kinase path-
genic stimulation and in response to g irradiation. BRCA1 way. Western blot analysis of cellular lysates from UBR60-bcl2 cells,
grown in the presence or absence (24 hr) of tetracycline, usingexpression was not associated with induction of other
antibody against p42 and p44 MAK kinase (Erk1 and Erk2) and theimmediate early genes, including c-MYC, c-FOS, c-JUN,
catalytically activated, Tyr-204 phosphorylated forms. MEK-phos-JUN B, or JUN D (data not shown), indicating that its
phorylated, bacterially expressed p42 MAK kinase (1) or a mutantinduction of EGR1 was not the result of nonspecific
(2) is shown as a control for the antibodies.
mitogenic stimulation. In contrast to GADD45, EGR1
demonstrated a delayed time course of induction follow-
ing expression of BRCA1 (Figure 5A). Also, in contrast find altered expression of p53 target genes or bcl2 family
to GADD45, the induction of EGR1 by BRCA1 was abro- members following induction of BRCA1, we observed
gated following disruption of JNK/SAPK signaling (see consistent activation of JNK/SAPK (Figures 6A and 6B).
below). The induction of EGR1 by BRCA1 may therefore Induction of BRCA1 led to phosphorylation of endoge-
be indirect, resulting from the regulation by JNK/SAPK nous JNK/SAPK and to increased kinase activity, com-
of known serum-responsive elements within the EGR1 parable to that observed following UV irradiation, the
promoter (Lim et al., 1998). most potent known inducer of JNK/SAPK. To confirm
that activation of JNK/SAPK in U2OS cells was not uni-
versally observed following the triggering of apoptosis,Activation of JNK/SAPK by BRCA1
The observation that BRCA1 induces expression of we analyzed U2OS cells stably expressing a CMV-driven
temperature-sensitive p53 allele (tsp53), which inducesGADD45 and triggers apoptosis in UBR60-bcl2 cells is
of particular interest, given the recent discovery that rapid cell death following switching to the permissive
temperature (328C). No increase in JNK/SAPK activityGADD45 may bind to the stress-responsive MTK1/MEKK4
MAPKKK, leading to JNK/SAPK-dependent apoptosis was observed following overexpression of wild-type p53
(Figure 6A). Also, induction of BRCA1 expression did(Takekawa and Saito, 1998). Indeed, while we did not
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Figure 7. Abrogation of BRCA1-Mediated Apoptosis by a Dominant-Negative Mutant of SEK1, Encoding the Kinase Upstream of JNK/SAPK
(A) Northern blot analysis of UBR60-bcl2 and their derivatives with constitutive expression of the dominant-negative SEK1 mutant (UBR60-
bcl2-dnSEK cells) to demonstrate expression of endogenous SEK1 and the transfected dominant-negative mutant (dnSEK1), and unaltered
inducible expression of BRCA1 and GADD45 in these two cell lines following tetracycline withdrawal. Loading control, GAPDH.
(B) Reduction in phosphorylation of endogenous JNK/SAPK, following induction of BRCA1 in cells expressing the dominant-negative SEK1
mutant. UBR60-bcl2 and UBR60-bcl2-dnSEK cells were grown in the presence or absence (36 hr) of tetracycline, followed by immunoprecipita-
tion with anti-JNK antibody and immunoblotting with anti-phospho-JNK antibody (P-JNK). Immunoblotting with anti-JNK antibody is shown
as a control for the efficiency of immunoprecipitation (JNK).
(C) Growth curves of UBR60-bcl2 and UBR60-bcl2-dnSEK cells, in the presence of tetracycline or following induction of BRCA1 expression.
Viable cells were counted, and standard deviations are given.
not result in nonspecific activation of the MAP kinase Discussion
pathway, as shown by the unaltered tyrosine phosphor-
ylation of MAP kinase (ERK1 and ERK2) (Figure 6C). By generating cell lines with tightly regulated inducible
expression of BRCA1 and expression profiling usingTo determine whether activation of JNK/SAPK was
required for BRCA1-mediated apoptosis, we stably trans- high-density oligonucleotide arrays, we have identified
a downstream pathway that is likely to contribute to thefected UBR60-bcl2 cells with a dominant-negative mu-
tant of SEK1, the common upstream regulator of JNK/ function of BRCA1 as a tumor suppressor. Induction of
BRCA1 expression in osteosarcoma and in breast can-SAPK family members (Yan et al., 1994). The resulting
cells were called UBR60-bcl2-dnSEK. Constitutive ex- cer cells triggers apoptosis. This effect involves induc-
tion of the DNA damage±responsive gene GADD45 andpression of the dominant-negative SEK1 mutant was
demonstrated by Northern blotting (Figure 7A), and im- is associated with activation of the JNK/SAPK stress
response pathway. Inhibition of JNK/SAPK signaling bymunoprecipitation experiments showed reduced phos-
phorylation of endogenous JNK/SAPK in these cells fol- expression of a dominant-negative mutant of SEK1 ab-
rogates BRCA1-mediated cell death. The induction oflowing the induction of BRCA1 (Figure 7B). Neither the
inducible expression of BRCA1 nor its induction of GADD45 expression and JNK/SAPK-dependent apo-
ptosis by BRCA1 are independent of p53, another tumorGADD45 was altered by constitutive expression of the
dominant-negative SEK1 mutant (Figure 7A). UBR60- suppressor involved in the response to DNA damage
and postulated to interact with BRCA1. These resultsbcl2-dnSEK cells also displayed a growth rate identical
to that of the parental UBR60-bcl2 cells in the presence suggest a functional pathway for BRCA1-mediated apo-
ptosis, consistent with a role in the p53-independentof tetracycline (Figure 7C), indicating that expression of
the SEK1 mutant did not itself alter cellular proliferation. cellular response to DNA damage.
Remarkably, however, induction of BRCA1 expression
in these cells failed to trigger apoptosis, suggesting that Induction of JNK/SAPK-Mediated
Apoptosis by BRCA1disruption of JNK/SAPK signaling antagonizes BRCA1-
mediated cell death (Figure 7C). As a control, we also The primary phenotype observed following forced ex-
pression of wild-type BRCA1 is programmed cell death.transfected the dominant-negative SEK1 mutant into
U2OS cells expressing the temperature-sensitive p53 This effect is so prompt that BRCA1 expression is de-
tectable for only 24 hr following withdrawal of tetracy-allele. Inhibition of JNK/SAPK function in these cells had
no effect on p53-mediated apoptosis (data not shown). cline, whereupon cells expressing BRCA1 are lost from
Induction of GADD45 and JNK/SAPK by BRCA1
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the culture and replaced with cells whose inducible pro- in the p53-independent activation of GADD45 will need
to be confirmed once genetically defined BRCA1-nullmoter has been silenced through hypermethylation. The
characterization of this cell death process as apoptotic cells are available. We did not observe activation of the
proximal GADD45 promoter following overexpression ofis based on its abrogation by peptides that specifically
inhibit the caspases required for apoptosis, as well as BRCA1 itself, in either transient transfection assays or
following stable chromosomal integration of reporterits delay by constitutive expression of the antiapoptotic
gene bcl2. PARP cleavage and TUNEL staining, charac- constructs (data not shown). The BRCA1-responsive
site may therefore be located at some distance fromteristics of cells undergoing apoptosis, are evident as
the protective effect of ectopically expressed bcl2 is known GADD45 regulatory sequences.
Our observations have implications for the paradoxi-overwhelmed. BRCA1-induced cell death appears to be
mediated primarily through the JNK/SAPK stress re- cal interactions between BRCA1 and p53. While BRCA1
activates the p21 promoter, either alone or in coopera-sponse pathway. Signaling through JNK/SAPK is known
to be triggered by UV irradiation, osmotic stress, and in tion with p53 (Somasundaram et al., 1997; Ouichi et al.,
1998; Zhang et al., 1998), BRCA1-null embryos demon-response to cytokines and growth factors, and it has
recently been implicated as a major apoptotic pathway strate increased expression of p21 and their phenotype
is partially rescued in a p21-null background, suggestingfollowing DNA damage and in response to Fas ligand
and tumor necrosis factor a (TNFa) (Chen et al., 1996; a functionally antagonistic relationship between BRCA1
and p53 (Hakem et al., 1997; Ludwig et al., 1997). BRCA1Rosette and Karin, 1996). Overexpression of BRCA1
may therefore mimic its activation in response to DNA does induce a modest, p53-dependent activation of a
reporter containing the p53-responsive element in introndamage, triggering a potent apoptotic response.
A potential mechanism for the activation of JNK/SAPK 3 of GADD45, but BRCA1-mediated induction of endog-
enous GADD45 is largely independent of p53. We alsoby BRCA1 is provided by its induction of GADD45, a
gene whose product has recently been reported to bind have observed neither activation nor repression of en-
dogenous p21, following inducible expression of BRCA1.and activate an upstream regulator of JNK/SAPK, the
MAPKKK MTK1/MEK4, triggering JNK/SAPK-depen- The cooperative effect of BRCA1 and p53 in promoter-
reporter assays therefore may not predict a physiologi-dent apoptosis (Takekawa and Saito, 1998). It is unclear
whether GADD45 is required for the activation of JNK/ cal effect on endogenous target genes, at least in the
cell lines that we examined. The increased expressionSAPK in response to DNA damage, and analysis of
GADD45-null cells will be required to determine whether of p21 in BRCA1-null embryos is unlikely to result from
loss of BRCA1-mediated transcriptional repression, butit is necessary for BRCA1-mediated apoptosis. GADD45
itself may have additional functional properties. In this rather from the activation of p53 in response to the
accumulation of DNA damage.context, it is of interest to note that preventing BRCA1-
mediated apoptosis by constitutive expression of the
dominant-negative SEK1 mutant uncovered a cellular Expression Profiling to Define Functional Pathways
proliferation defect in cells overexpressing BRCA1 (Fig- Finally, the identification of downstream targets of
ure 7C). This was associated with marked prolongation BRCA1 by expression profiling using oligonucleotide
of both S and G2/M phases, culminating in the appear- arrays demonstrates the potential utility of this strategy
ance of large cells with abundant cytoplasm, staining in defining functional pathways for individual gene prod-
for the cellular senescence marker b-galactosidase (data ucts (Lockhart et al., 1996; Wodicka et al., 1997). The
not shown). Further experiments will be required to de- signal amplification associated with an inducible gene
termine whether this phenotype is also dependent upon overexpression model facilitates the detection of target
GADD45 expression. genes, and the magnitude of inducible expression in
the cells analyzed (approximately 60-fold BRCA1 mRNA
induction and 3-fold protein induction) is consistent withInduction of GADD45 by BRCA1 and Its Potential
Role in Transcriptional Activation the elevated physiological levels of BRCA1 expression
observed in tissues undergoing proliferation and differ-The identification of GADD45 as an endogenous gene
that is rapidly induced following BRCA1 expression pro- entiation (Lane et al., 1995; Marquis et al., 1995). None-
theless, the consequences of BRCA1 overexpression invides a physiological target to study the potential role
of BRCA1 in transcriptional regulation. Induction of U2OS and MDA435 cells may only provide a simplistic
model of its physiological function, which may also beGADD45 by BRCA1 was virtually immediate, and it was
unaffected by expression of the dominant-negative SEK1 modulated by protein phosphorylation and possible in-
teractions with other coregulated proteins. Regulatedmutant. Of note, BRCA1-mediated induction of GADD45
was independent of p53. While GADD45 has served as a overexpression of tumor suppressors, such as p53, has
also proven useful for identifying critical downstreamcritical marker for the ATM- and p53-dependent cellular
response to DNA damage following IR (Fornace et al., target genes, using either subtractive hybridization (El-
Deiry et al., 1993) or SAGE, a strategy that requires1988; Kastan et al., 1992), p53-independent activation
of GADD45 has been observed following treatment with sequencing large numbers of multimerized cDNA tags
(Velculescu et al., 1995). By comparison, hybridization-MMS (Hollander et al., 1993). The observation that a
BRCA1 mutant breast cancer cell line fails to induce based expression profiling affords high-throughput analy-
sis of multiple specimens.GADD45 following treatment with MMS therefore raises
the possibility that BRCA1 may play an integral role Expression profile analyses in yeast have been re-
ported using oligonucleotide arrays, allowing the demon-in this DNA damage response pathway. Nonetheless,
multiple genetic alterations are likely to be present in stration of altered gene expression patterns associated
with different growth conditions, genetic backgrounds,this breast cancer cell line, and a requirement for BRCA1
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the proximal GADD45 promoter (1 to 2994 bp, upstream of theand cell cycle inhibitors (Wodicka et al., 1997; Cho et
transcriptional start site), from intron 3 (11553 to 11695 bp), whichal., 1998). Similar comparisons in mammalian cells are
is known to contain a p53-responsive site, and from introns 1 (1339predicted to show large differences in expression pat-
to 1824 bp) and 2 (1930 to 11160 bp) (Hollander et al., 1993). U2OS
terns between different tissues, between normal and cells were transfected by calcium phosphate DNA precipitation with
cancer cells, and following general proliferative signals 5 mg of CMV-driven BRCA1, along with 2 mg of the reporter con-
structs and 1 mg of a construct encoding human growth hormonesuch as serum stimulation (Iyer et al., 1999). Our obser-
(HGH; Nichols Institute). The amount of transfected CMV promotervations now demonstrate the application of this ap-
sequence was equalized by addition of vector, and extracts wereproach to defining specific downstream targets for an
standardized for transfection efficiency by quantitation of HGH inindividual gene product. This analysis requires the ability
the culture medium. Luciferase activity was assayed using standard
to reliably detect expression changes in a smaller procedures, and all transfection experiments were performed in
number of genes and of a lower magnitude than for duplicate.
comparison between grossly different cell types. Our
Antibodies and Immunological Analysesexperiments indicate that many potential BRCA1 targets
Antibodies against BRCA1 included the mouse monoclonal antibod-registered by oligonucleotide arrays were confirmed by
ies MS13 and MS110 (Oncogene Science), the rabbit polyclonalNorthern blotting, supporting the accuracy of this tech-
antibodies C20 and D20 (Santa Cruz), and monoclonal antibody 12-
nique. In most cases, discrepancies were attributable CA-5 directed against the synthetic HA epitope. Antibody against
to the lower sensitivity of Northern analysis, although in p21 (CP36) and p53 (PAb122) were kindly provided by E. Harlow,
and antibodies to bax (N20) and PARP (C2-10) were purchased fromsome cases, interreplicate variation may have contrib-
Santa Cruz and Biomol, respectively. TUNEL assays were performeduted to discordant results. Monitoring the time course
using standard protocols (Oncor). Expression of BRCA1 was dem-of target gene induction following BRCA1 expression
onstrated by extraction of cellular lysates using RIPA buffer, immu-and analyzing results derived from multiple experimental
noprecipitation with antibodies C20 or D20, followed by Western
replicates appear to be a valuable strategy for the identi- blot analysis using either antibody 12-CA-5 or MS110. Activation
fication of specific downstream targets. As more complex of JNK/SAPK was measured 24 hr following induction of BRCA1
expression, before apoptotic cells were evident. Cellular lysatescomparisons of expression profiles are undertaken, and
were extracted, standardized for protein content, immunoprecipi-as array density is increased to cover all known tran-
tated with antibody to JNK/SAPK (C17; Santa Cruz), and incubatedscription units in mammalian cells, the optimization of
with GST-c-Jun in the presence of [g32P]ATP. JNK/SAPK phosphory-experimental approaches and the development of novel
lation was assayed by immunoprecipitation using antibody C17,
data mining tools will become invaluable. followed by Western blotting with anti-phospho-JNK antibody
(NEB). To demonstrate UV-mediated induction of JNK/SAPK activ-
ity, lysates were prepared 1 hr after treatment of cells with 20 J/m2
Experimental Procedures of UV-B, in the absence of culture medium. Activation of the MAP
kinase pathway was analyzed by immunoblotting of cellular lysates
Generation of Cells with Inducible BRCA1 Expression using antibody against p42 and p44 MAP kinase (Erk1 and Erk2)
A full-length BRCA1 construct was assembled from partial cDNA and the catalytically activated, Tyr-204 phoshorylated forms (p44/
clones isolated from a human testis cell library, confirmed as wild- p42 MAPK and phospho-MAPK antibodies; NEB). For immunofluo-
type by sequencing the entire coding region, and cloned, along rescence analysis, cells were grown on coverslips, fixed with 4%
with a 59 HA epitope tag, downstream of the tetracycline-regulated paraformaldehyde, permeabilized with 1% Nonidet P-40/10 mM gly-
promoter in pUHD10-3 (Gossen and Bujard, 1992). A mutant BRCA1 cine, preadsorbed with 3% bovine serum albumin, treated with
construct was generated by PCR, causing premature termination antibody MS13 (1:200) or 12-CA5 (1:10) followed by rhodamine-
within exon 11 (nucleotide 1259) and encoding a truncated protein conjugated affinity-purified goat anti-mouse IgG (1:400; Jackson
of 50 kDa. An U2OS osteosarcoma founder cell line UAT5 stably ImmunoResearch).
expressing the tetracycline-VP16 transactivator was used to gener-
ate stably transfected clones: UBR60, with tightly regulated induc- Oligonucleotide Array±Based Expression Profiling
ible expression of wild-type BRCA1, and UBR-mt with comparable Messenger RNA was isolated from UBR60-bcl2 cells at 0, 6, 12, and
expression of the mutant construct. The breast cancer cell line 24 hr following BRCA1 induction. Analysis of polyadenylated and
MDA435 was used to generate another founder cell line, MDA47, total mRNA yielded similar results. The RNA was amplified, labeled,
from which was derived the MBR62 cell line with inducible wild-type and hybridized to oligonucleotide arrays as described elsewhere
BRCA1. The breast cancer cell line HCC1937 was kindly provided (Lockhart et al., 1996; Wodicka et al., 1997). Each RNA sample was
by Dr. Gail Tomlinson (Southwestern Medical Center). To test for hybridized to a set of four arrays, which together enabled interroga-
promoter hypermethylation, UBR60 cells that had lost inducible ex- tion of the expression levels of 6800 human genes and ESTs. Minimal
pression following prolonged growth in tetracycline were treated variation was observed following independent hybridization of iden-
with 2 mg/ml 5-azaC (Sigma) for 24 hr on days 1 and 4, followed by tical RNA samples, and no significant expression differences were
withdrawal of tetracycline on day 7, RNA isolation on day 8, and found to be induced in U2OS cells by the presence or absence of
Northern blot analysis. Cell lines with constitutive expression of tetracycline itself. Following quantitative expression analysis (Lock-
CMV-driven bcl2 or HPV16 E6 were generated by stable transfection hart et al., 1996; Wodicka et al., 1997), a list of candidate BRCA1
of UBR60 cells along with a hygromycin resistance plasmid. Cells targets was assembled by identifying genes that were progressively
with constitutive expression of the CMV-driven dominant-negative induced or repressed in at least two different time points and dis-
SEK1 mutant (kindly provided by L. Zon, Harvard Medical School) played an expression change of at least 2-fold. All targets were
were generated by cotransfection with XGPT and selection in HAT. verified by Northern analysis, followed by quantitation of signal using
Multiple clones expressing the stably transfected constructs were a PhosphorImager (Biorad).
analyzed to ensure against the effects of clonal selection. For cas-
pase inhibition, cells were treated with the synthetic, cell-permeable, Acknowledgments
noncleavable analog of caspase CPP32 (0.2 mM; Clontech). Colony
formation was assayed by withdrawal of tetracycline and staining We thank I. Stamenkovic, C. L. Parng, N. Dyson, J. Settleman, and S.
of colonies after 7 days in culture. For growth curves, viable cells van den Heuvel for their valuable advice and for providing important
were counted using staining with methylene blue. reagents. This work was supported by National Institutes of Health
For promoter reporter assays, the pGL3 backbone (Promega) was grant CA58596 (D. A. H.).
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